SCHEMBL2372671

SCHEMBL2372671

OCCN1CCN(c2cnc(Nc3nccc4nc(-c5c(F)cccc5Cl)[nH]c34)cn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.54
TYK2 P29597 6/20 0.54
PTPN11 Q06124 2/20 0.41
SRC P12931 4/20 0.38
HTR2A P28223 3/20 0.36
WEE1 P30291 2/20 0.36
LCK P06239 3/20 0.35
LYN P07948 3/20 0.35
KDR P35968 2/20 0.35
INSR P06213 1/20 0.35
CDK1 P06493 1/20 0.35
CDK4 P11802 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNA2 P20248 1/20 0.35
CCND1 P24385 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
PKMYT1 Q99640 3/20 0.35
EPHB6 O15197 2/20 0.35
ABL1 P00519 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2372075 0.94 JAK2 (0.59) JAK2TYK2SRCHTR2AWEE1
SCHEMBL2372424 0.89 TYK2 (0.50) JAK2TYK2WEE1CDK1CDK4
SCHEMBL2371361 0.88 TYK2 (0.70) JAK2TYK2PTPN11SRCHTR2A
SCHEMBL2386545 0.87 TYK2 (0.50) JAK2TYK2PTPN11ABL1MAPK14
SCHEMBL2372126 0.87 JAK2 (0.56) JAK2TYK2SRCHTR2AWEE1
SCHEMBL2369933 0.86 TYK2 (0.54) JAK2TYK2SRCHTR2AWEE1
SCHEMBL2371567 0.84 JAK2 (0.46) JAK2TYK2PTPN11SRCABL1
SCHEMBL2372556 0.83 JAK2 (0.55) JAK2TYK2WEE1CDK1CDK4
SCHEMBL2371602 0.82 TYK2 (0.78) JAK2TYK2SRCHTR2AWEE1
SCHEMBL2372389 0.81 JAK2 (0.61) JAK2TYK2SRCHTR2AWEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
EP-2547338-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2013-01-23 EP disclosed
WO-2011113802-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 WO disclosed
WO-2011113802-A2 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 JAK2 6/4885TYK2 1/4885PTPN11 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.